No immediate trading signal. Monitor future Form 4 filings from Patni for any open-market purchases or sales, which would provide insider conviction signals. The appointment itself is neutral for the stock.
SEPN drugs
SEPN drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+20- T+0 · Sep 4 $36.75entry
- T+1 · 2mo ago +1.69%α +2.24% · $37.37
- T+5 · 2mo ago +7.62%α +8.83% · $39.55
- T+20 · 6w ago +3.05%α +2.45% · $37.87
- T+50 · todayOpen
- T+60 · in 14d Pending
Price Chart
How similar events traded
Executive Summary
Rajiv Patni, M.D., has been appointed Chief Medical Officer of Septerna, Inc. and filed a Form 3 initial statement of beneficial ownership, along with a limited power of attorney authorizing certain company officers to execute future Section 16 filings on his behalf. This is a routine administrative filing for a new officer and contains no financial data, trading activity, or material corporate event.
Key Facts
- Rajiv Patni, M.D. appointed as Chief Medical Officer of Septerna, Inc.
- Form 3 filed on 2026-09-03 with a period of report of 2026-08-24
- Limited power of attorney executed on 2026-08-18 authorizing Jeffrey Finer, Elizabeth Bhatt, Gil M. Labrucherie, Mark A. Wilson, and Ran Xiao to file Section 16 forms
- No beneficial ownership or trading data disclosed in the filing
Financial Impact
No financial impact, routine officer onboarding filing with no disclosed ownership or transactions.
Risk Factors
- No material risks identified from this filing
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 3 Filing (Primary) | 0001193125-26-382268 |
| Document: 0001193125-26-382268-index-headers.html | 0001193125-26-382268 |
| Document: 0001193125-26-382268-index.html | 0001193125-26-382268 |
| Document: 0001193125-26-382268.txt | 0001193125-26-382268 |
Track record
25 reports on SEPN
7 of 7 bullish or bearish reports moved the stock their way by T+5. Best: +55.96% at T+60 after the Apr 13, 2026 report. 8 of 8 went positive at some point.
Filters
- Nov 16, 2026today Insider Cluster Neutral 2/10 Entry price pending
- Nov 16, 2026today 144 Neutral 2/10 Entry price pending
- Nov 12, 20264d ago 144 Neutral 3/10 Entry $42.60 Now $42.60 −0.00% settles Nov 20
- Nov 12, 20264d ago 144 Neutral 2/10 Entry $42.60 Now $42.60 −0.00% settles Nov 20
- Nov 12, 20264d ago 144 Neutral 3/10 Entry $41.86 Now $42.60 +1.77% settles Nov 19
- Nov 9, 20267d ago Press Release Bearish 5/10 Entry $52.34 Now $42.60 +18.61% settles Nov 17
- Nov 4, 202612d ago 8-K Neutral 3/10 Entry $47.88 to $48.56 Now $42.60 −11.03% ▲ +1.42% +2.33% vs SPY
- Nov 4, 202612d ago Press Release Neutral 4/10 Entry $47.88 to $48.56 Now $42.60 −11.03% ▲ +1.42% +2.33% vs SPY
- Sep 10, 20269w ago Press Release Neutral 2/10 Entry $38.51 to $38.69 Now $42.60 +10.62% ▲ +0.47% +0.69% vs SPY
- Sep 3, 202610w ago 3 Neutral 2/10 Viewing Entry $36.75 to $39.55 Now $42.60 +15.92% ▲ +7.62% +8.83% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers